Previous 10 | Next 10 |
LEXINGTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Chief Executive Officer (CEO), John Sperzel, has promoted Tony Pare to t...
On a preliminary basis , T2 Biosystems (NASDAQ: TTOO ) expects Q4 revenue of ~$3.0M, including ~$1.5M in product sales. It also closed 10 T2Dx contracts in the quarter. More news on: T2 Biosystems, Inc., Healthcare stocks news, Stocks on the move, Read more ...
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced preliminary revenue and business results for the three months ended December 31, ...
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Board of Directors has appointed diagnostics industry veteran John Sperz...
Aravive (NASDAQ: ARAV ) +212% on promise of lead candidate . More news on: Aravive, Inc., Cancer Genetics, Inc., My Size, Inc., Stocks on the move, Read more ...
LEXINGTON, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in h...
T2 Biosystems, Inc. (TTOO) Q3 2019 Earnings Conference Call November 12, 2019 8:30 a.m. ET Company Participants Zack Kubow - W2O Group John McDonough - Chairman and CEO John Sprague - CFO Tom Lowery - Chief Scientific Officer Conference Call Participants Puneet Souda - SV...
Solid Biosciences (NASDAQ: SLDB ) -71% on another clinical hold on DMD gene therapy . More news on: Solid Biosciences Inc., Diplomat Pharmacy, Inc., Fluent, Inc., Stocks on the move, Read more ...
T2 Biosystems ( TTOO ) Q3 results : Revenues: $1.6M; Product revenue: $1.4M (+17%); Research and grant contribution revenues: $0.2M. More news on: T2 Biosystems, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
LEXINGTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in h...
News, Short Squeeze, Breakout and More Instantly...
LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (ȁ...
2024-05-17 18:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregat...